Formerly known as the International AIDS Conference (IAC), the first AIDS event took place in Atlanta in 1985 and was organised by the Centers for Disease Control and Prevention (CDC), the World Health Organisation (WHO), and Emory University. More than 2000 scientists, activists and public health officials came together to share information on HIV and AIDS as an emerging epidemic. Now organised by the International AIDS Society (IAS), the AIDS 2024 conference is expected to host over 15,000 scientists, healthcare professionals and people living with and affected by HIV to share the latest data and lessons learnt from the HIV response over the past 40 years.
The 25th InternatIonal AIDS Conference
Join us at AIDS 2024, the 25th International AIDS Conference (IAS), happening in Munich, Germany from 22-26 July.
This conference is a crucial platform for us to showcase our latest advances in HIV treatment and prevention innovation, as well as our long-standing partnership with the HIV Community.
The dynamic and vibrant atmosphere in the village is always a highlight of the conference and we look forward to seeing you all there.
SHOWCASING OUR INNOVATIVE PORTFOLIO AND PIPELINE AT AIDS 2024
Our ultimate goal is simple; to end the HIV epidemic. Until then, we will continue to explore new ways of treating and preventing HIV in order to achieve our mission of leaving no person living with HIV behind.
Abstracts from our innovative pipeline and portfolio will emphasise our commitment to meeting the evolving wants and needs of the HIV community, including new data and findings for our existing HIV therapies, as well as the next generation, including 2-drug and long-acting regimens.
Highlights will include head-to-head data assessing treatment efficacy, safety and weight gain of oral regimens. Additionally, findings will be presented from therapies currently in our pipeline including first-time-in-human data for a third-generation INSTI, with data on potential ultra long-acting applications. These will be just some of the initial findings from our highly innovative pipeline, as we continue our work to evaluate these medicines in clinical trials involving a diverse group of people living with HIV. In addition, we also continue to generate and present clinical trial findings and real-world evidence from across our portfolio of our marketed long-acting medicines, assessing our long-acting HIV prevention regimen for safety in pregnant women, and our long-acting treatment regimens for safety, efficacy and patient perspectives.
Hear from the scientists in our Branford labs.
We know that people living with HIV and those who can benefit from PrEP want more options and that’s why we’re exploring new ways of treating and preventing HIV through new approaches in how we target the virus as well as the process of how medicines are administered.
You can find out more about the conference programme here.
PARTNERING WITH THE COMMUNITY
We’re proud of our enduring commitment to the HIV community, whether it be through our 30+ year Positive Action Programme or through our digital campaigns, collaborating as partners, advocates, and champions to address the issues that matter most.
At AIDS 2024, we’ll be using our platform to amplify the voices of the HIV community, ensuring that their voices are heard, shining a spotlight on the communities that are disproportionately impacted by HIV.
Find us here:
Save the date and mark your calendars for AIDS 2024 in Munich, where innovation, collaboration, and progress converge for the benefit of all those living with and impacted by HIV.
OUR ULTIMATE GOAL: TO END THE HIV EPIDEMIC
Thanks to advances in science and innovation, people living with HIV have options for effective treatment that mean they can expect to live long and healthy lives. Find out why understanding the needs and wants of people living with HIV is essential.
At ViiV healthcare, our goal is ambitious, yet clear: we want to end the HIV epidemic. We believe we have the tools to achieve this goal through continuous innovation, talented people and global partnerships that help us reach the communities that are disproportionately impacted by HIV. We must keep investing in the global HIV response.
For people living with HIV. Resources and information about living well with HIV.
NP-GBL-HVX-COCO-240034 | July 2024
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
